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ABSTRACT
Measuring antibiotic-induced killing relies on time-consuming biological tests. The firefly luciferase gene (luc)
was successfully used as a reporter gene to assess antibiotic efficacy rapidly in slow-growing Mycobacterium
tuberculosis. We tested whether luc expression could also provide a rapid evaluation of bactericidal drugs in
Streptococcus gordonii. The suicide vectors pFW5luc and a modified version of pJDC9 carrying a promoter-
less luc gene were used to construct transcriptional-fusion mutants. One mutant susceptible to penicillin-in-
duced killing (LMI2) and three penicillin-tolerant derivatives (LMI103, LMI104, and LMI105) producing lu-
ciferase under independent streptococcal promoters were tested. The correlation between antibiotic-induced
killing and luminescence was determined with mechanistically unrelated drugs. Chloramphenicol (20 times
the MIC) inhibited bacterial growth. In parallel, luciferase stopped increasing and remained stable, as de-
termined by luminescence and Western blots. Ciprofloxacin (200 times the MIC) rapidly killed 1.5 log10
CFU/ml in 2–4 hr. Luminescence decreased simultaneously by 10-fold. In contrast, penicillin (200 times the
MIC) gave discordant results. Although killing was slow (#0.5 log10 CFU/ml in 2 hr), luminescence dropped
abruptly by 50–100-times in the same time. Inactivating penicillin with penicillinase restored luminescence,
irrespective of viable counts. This was not due to altered luciferase expression or stability, suggesting some
kind of post-translational modification. Luciferase shares homology with aminoacyl-tRNA synthetase and acyl-
CoA ligase, which might be regulated by macromolecule synthesis and hence affected in penicillin-inhibited
cells. Because of resemblance, luciferase might be down-regulated simultaneously. Luminescence cannot be
universally used to predict antibiotic-induced killing. Thus, introducing reporter enzymes sharing mechanis-
tic similarities with normal metabolic reactions might reveal other effects than those expected.
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INTRODUCTION
TESTING THE ACTIVITY OF ANTIBACTERIAL DRUGS includes de-termining both their bacteriostatic and bactericidal effects.
The bacteriostatic activity is quantified by their minimal in-
hibitory concentration (MIC).1 The bactericidal activity as-
sesses their ability to block irreversibly the resumption of cell
division after removal of the drug from the medium. Both de-
terminations are useful in predicting antibiotic treatment suc-
cess. Being bactericidal is an important antibiotic property in
circumstances of altered host defenses. This includes infections
in the neutropenic patient and infections confined to so-called
therapeutic sanctuaries, such as in infectious endocarditis and
bacterial meningitis.
However, determination of these two parameters utilizes mi-
crobial growth as readout. Therefore, depending on the bacte-
rial doubling time, it may take days to weeks to obtain the re-
sults. Attempting to circumvent this limitation Jacobs et al.15
introduced the firefly luciferase gene (luc) into Mycobacterium
tuberculosis and determined the luminescence of bacteria in the
absence or presence of antibiotics. The luc product is a 62-kDa
protein that does not require post-translational processing.5,34
Thus, it can be functionally expressed by a variety of eukary-
otic and prokaryotic cells.11,15 It generates light by oxidizing
beetle luciferin in an ATP-dependent manner, and has one of
the highest quantum yields.28 This makes it an excellent sensi-
tive real-time reporter for assessing the energy level of the re-
cipient bacterium.
Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
23
94
6 
| 
do
wn
lo
ad
ed
: 
8.
5.
20
16
In their experiment, Jacobs et al. used a broad-spectrum lytic
phage carrying the luc gene to infect M. tuberculosis.15 Upon
infection, recipient bacteria transiently transcribed the phage-
encoded luc gene and emitted a burst of light. When antibiotics
were added to the culture, the burst of light was inhibited in
susceptible bacteria, but persisted in resistant organisms. Thus,
the system allowed the discrimination between drug-suscepti-
ble and drug-resistant M. tuberculosiswithin hours as compared
to days or weeks with conventional methods.
Recently, the system was improved by constructing a stable
luc-positive lysogen in M. smegmatis,27 to facilitate screening
of new antimycobacterial drugs. Firefly luciferase was suc-
cessfully used by Loimaranta et al.17 and Tenhami et al.30 to
test the bacteriostatic effect of a variety of antibiotics against
Streptococcus mutans and Staphylococcus aureus, respectively.
However, none of the reported studies tested the activity of lu-
ciferase to predict antibiotic-induced killing.
Luciferase has a few theoretical features making it a suitable
candidate to rapidly assess antibiotic-induced killing. First, in-
tracellular luciferase activity requires the reporter organism to
be physically intact. Thus, it would readily detect killing due
to drug-induced bacterial lysis. Second, light emission requires
the microorganism to produce ATP. Therefore, any membrane
or metabolic alterations resulting in de-energizing the bacterial
cell—a kind of alteration that is expected in dead cells—would
be detected by a switch off of luminescence. Third, measuring
luminescence in bacteria is technically easy and instantaneous.
Thus, it would generate an online profile that could detect both
lysis-independent and lysis-dependent killing in a much more
rapid way than subculturing bacteria on agar plates as in stan-
dard time-kill experiments.1
The present experiments explored this possibility using an
isogenic pair of luciferase-positive Streptococcus gordonii that
were either susceptible or tolerant to penicillin-induced killing.
Mechanistically unrelated drugs, including chloramphenicol,
ciprofloxacin, and penicillin, were used. The luc-reporter sys-
tem was tested under independent streptococcal promoters af-
ter insertion into the streptococcus.
MATERIALS AND METHODS
Microorganisms and growth conditions
Streptococcus gordonii Challis25 and its various transfor-
mants are described in Table 1. Escherichia coli DH5a was
used for plasmid propagation. Streptococci were grown at 37°C
either in brain heart infusion broth (BHI; Difco laboratories,
Detroit, MI) without aeration, or on Columbia agar (Becton
Dickinson Microbiology Systems, Cockeysville, MD) supple-
mented with 3% blood. E. coli were grown in Luria Bertani
(LB) broth or on LB agar. Growth of the cultures was followed
both by optical density at a wavelength of 620 nm (OD620) with
a spectrophotometer (Sequoia-Turner, Montainville, CA) and
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TABLE 1. BACTERIAL STRAINS USED IN THE STUDY AND SUSCEPTIBILITY TO PENICILLIN-INDUCED KILLING
S. gordonii Source or
strains Relevant genotype Phenotype/utilization 2 hr 4 hr 24 hr reference
Challis (parent) Wild type Reference strain 0.5 1 3–4 2,25
LMI 2 Parent V pFWD5luc Spr Luc1/expresses luc under a 0.5 1 3–4 This work
chromosomal promoter
Tol1c Penicillin-tolerant Tol1 Smr/selected by repeated 0.2 0–0.5 0.5–1 2
mutant of S. gordonii penicillin passages
Tol103b Tol1 arcB; ; luc-erm Tol1 Luc1 Emr Smr/expresses 0.2 0–0.5 0.5–1 2
luc under the arc promoter
Tol104c Tol1 V pFWD5luc Tol1 Luc1 Spr 0.2 0–0.5 0.5–1 This work
Tol105d Tol1 scaA; ; luc-erm Tol1 Luc1 Emr/expresses luc 0.2 0–0.5 0.5–1 2,3
under the sca promoter
Spr, Spectinomycin resistant; Emr, erythromycin resistant; Smr, streptomycin resistant; arc, arginine deiminase operon; scaA,
Mn-binding membrane lipoprotein gene.3
aLoss of viability (in log CFU/ml) after addition of 2003 the MIC of penicillin (final concentration) to broth cultures of 
S. gordonii.
bTol1 mutant containing a luc transcriptional-fusion reporter inserted into the arcB gene by means of the pJDC9 erm1 suicide
vector.2
cThe pFWD5luc insert of mutant LMI2 was introduced into the Tol1 chromosome by transformation of Tol1 with LMI2 
chromosomal DNA.
dTol1 mutant containing a luc transcriptional-fusion reporter inserted into the scaA gene by means of the pJDC9 erm1 suicide
vector.2,3
Penicillin-induced killing
(log CFU/ml)a
by viable counts on agar plates. When appropriate, antibiotics
were added to the medium at the following concentrations:
spectinomycin (Sp) either 100 mg/L (for E. coli) or 500 mg/L
(for S. gordonii), erythromycin (Em) 5 mg/L, penicillin (Pn)
0.8 mg/L, chloramphenicol (Cm) 640 mg/L, and ciprofloxacin
(Cp) 200 mg/L. This corresponded to 200 times the MIC of
penicillin and ciprofloxacin and 20 times the MIC of chloram-
phenicol for the test S. gordonii. Bacterial stocks were stored
at 270°C in broth supplemented with 10% (vol/vol) glycerol.
Antibiotics and chemicals
Penicillin G was purchased from Aventis AG (Zurich,
Switzerland); ciprofloxacin was purchased from Bayer AG
(Wuppertal, Germany); D-luciferin, recombinant firefly lu-
ciferase and rabbit anti-luciferase antibodies were purchased
from Promega (Promega Corporation, Madison, WI); DNA-
modifying enzymes were purchased from Gibco Life Tech-
nologies (Gaithersburg, MD) and used according to the manu-
facturer’s recommendations. All other chemicals were
reagent-grade, commercially available products.
Antibiotic susceptibility and time-kill curves
The MICs of the test antibiotics were determined by a stan-
dard macrodilution method.1 Time-kill curves were determined
by adding appropriate concentrations of antibiotics to bacterial
cultures in the exponential phase of growth at an OD620 of 0.2.2
At various times before and after drug addition, samples were
removed and spread on agar plates for colony count. Antibiotic
carryover was avoided as described previously.7,8 Colonies
were counted after 48 hr of incubation at 37°C.
Construction of a luciferase transcriptional-fusion
reporter system in S. gordonii
DNA and competent cells were prepared by already-de-
scribed methods.2,25,26 Plasmids were purified with a plasmid
purification kit (Qiagen GmbH., Hilden, Germany). To insert
the Photinus pyralis firefly luciferase (luc) gene into the S.
gordonii chromosome, we used the suicide vector pFW5luc
(kindly provided by A. Podbielski, University of Ulm, Ulm,
Germany). This vector is derived from previous constructs
(pFW-phoA and pFW-gfp) used in promoter-probe experi-
ments.22 It contains the pUC19 origin for replication in E. coli
and a spectinomycin-resistance (Spr) marker. In addition, it
carries multicloning site located upstream of a promoterless
luc gene, containing its ribosome-binding site. This makes the
construct suitable for transcriptional-fusion experiments.12,23
pFW5luc cannot replicate autonomously in S. gordonii, but
can express Spr provided that it is inserted into the chromo-
some. To achieve integration, a Sau3A digest of the recipi-
ent’s chromosome was ligated at the BamHI site of the vec-
tor, just upstream of the luc gene. The mixture of plasmid
chimera was transformed into S. gordonii-competent cells. In-
tegration of the construct occurred by insertion-duplication.24
If the streptococcal DNA ligated upstream of luc contained a
promoter sequence, then luc was expected to be expressed by
the recombinant.29 Transformants were selected on Sp-con-
taining agar. Resistant colonies were picked, grown in antibi-
otic-containing liquid cultures, and screened for light emis-
sion. Additional constructs using a modified pJDC9 suicide
vector were also used (Table 1).2,3
Determination of light emission in whole cells
Light emission was measured by slight modifications of a
published method.15 Tubes containing fresh prewarmed BHI
broth were inoculated with 1/100 (vol/vol) from an overnight
culture and growth was followed as described. At several times
during logarithmic growth or after antibiotic addition, 100-ml
samples of the cultures were removed, added to 5 ml of poly-
styrene (753 12-mm) tubes containing 250 ml of sodium cit-
rate (pH 5.5) and equilibrated for 3 min at room temperature.
A pH of 5.5 was chosen to inactivate luciferase that might leak
from the cell into the extracellular milieu.6 Immediately before
light measurement, 50 ml of 1 mM beetle D-luciferin (Promega
Corporation, Madison, WI) diluted in 25 mM glycylglycine and
15 mM MgSO4 (GB buffer) were added to the mixture. The
tubes were transferred into the luminometer (Luminat LB9501,
EG & G Berchtold, Bad Wildbad, Germany) and the kinetics
of light emission were followed over 5 min. During the expo-
nential growth phase, light emitted by the bacteria peaked
within the first 20 sec of luciferase addition, and drastically de-
creased thereafter to reach a plateau after 5 min. In the present
experiments, peak luminescence was recorded and always de-
termined within the first 20 sec of light emission. Luminescence
was expressed in relative light unit per second (RLU/sec).
Determination of light emission in bacterial 
crude extracts
To evaluate the functionality of luciferase taken out of the
intracellular milieu, light emission was also measured in
crude extracts of bacteria. The microorganisms were grown
in 500-ml flasks. Samples (50–100 ml) were removed at var-
ious times after drug addition and chilled at 4°C; the bacte-
ria were recovered and washed twice in 0.9% NaCl by cen-
trifugation. The pellets were resuspended in 1 ml of a 50 mM
KPO4 pH 7.4 and 10 mM of MgSO4 solution. Specifically
using 10 mM of MgSO4 was important both because other
anions (e.g., MgCl2) inhibit luciferase activity, and higher salt
concentrations (e.g., $100 mM) shift light emission from yel-
low-green to red.6 The cells were mechanically broken
(.90% as assessed by phase contrast microscopy) as de-
scribed.18 Large debris and nonlysed cells were removed by
low-speed centrifugation (2000 rpm for 10 min). Protein con-
centration in the supernatant was determined by the bicin-
choninic acid (BCA) protein assay (Pierce Chemical, Rock-
ford, IL). Samples were stored at 230°C.
For light emission, 50 ml of a cell extract containing 5 mg
of protein was added to 200 ml of GB buffer (as above) sup-
plemented with 4 mM of EGTA (final concentration) and 9
ml of a 400 mM solution of ATP. After mixing, the tubes were
equilibrated for 3 min at room temperature before being trans-
ferred into the luminometer. D-Luciferin (100 ml) was added.
In contrast to the “flash light” kinetics observed in exponen-
tially growing bacteria, light emission was stable in this “ex
vivo” condition. Therefore, light output was measured start-
ing 0.2 sec after D-luciferin addition and integrated over a 
10-sec period of time. Recombinant luciferase was used as a
control.
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Luciferase detection by Western blot
To test for possible intracellular luciferase degradation, 10
mg of protein from crude extracts was separated by elec-
trophoresis on an 8% sodium dodecyl sulfate (SDS)-polyacryl-
amide gel.16 The proteins were transferred overnight (at 4°C)
onto an Immobilon-P PVDF membrane (Millipore Corporation,
Bedford, MA) using a Mini-Trans-Blot electrophoretic transfer
cell (Bio-Rad Laboratories, Hercules, CA) and a constant volt-
age of 35 V. The membranes were incubated with a final con-
centration of 0.5 mg/L of anti-luciferase polyclonal rabbit an-
tibodies for 4 hr. After repeated rinsing with PBS and 0.2%
Tween, the immunoblots were incubated for 1 hr with a
1:50,000 dilution of goat anti-rabbit antibodies coupled with al-
kaline phosphatase (Pierce). The bands were revealed by the
BCIP (5-bromo-4-chloro-3-indol-1-phosphate-p-toluidine)-ni-
troblue tetrazolium method (AP development Reagent; Bio-
Rad). Recombinant luciferase was used as a control.
RESULT
Construction of a luciferase transcriptional-fusion
reporter system
Competent S. gordonii cells were treated with 1 mg/ml (fi-
nal concentration) of pFWD5luc chimera containing random
Sau3A chromosomal fragments. The transformation rate to Spr
was 1026. Twelve resistant mutants were obtained in two ex-
periments. Four of them (33%) expressed luciferase. The fre-
quency of transcriptional fusion was comparable to previous
studies using this random-insertion technique.31
One Spr mutant (LMI 2) expressing high luciferase activity
over the whole exponential growth phase was further studied.
Figure 1 depicts the correlation between viable counts and light
emission during growth, and shows that luminescence corre-
lated with viable counts. Similar observations were made with
the luminescent tolerant derivatives Tol103, Tol104, and
Tol105 used as controls (Table 1).2,3
The stability of the chromosomal luc insert was tested by se-
rial passages in antibiotic-free broth followed by plating on se-
lective agar. Seventy-five percent of LMI 2 had lost their Spr
marker after ,35 generation times. Therefore, spectinomycin
was kept in the medium in subsequent experiments. The pres-
ence of the drug did not alter bacterial growth or antibiotic-in-
duced killing (data not shown). No attempt was made to deter-
mine the exact mechanism of this instability.
Finally, chain length variation could yield discordant results
between luminescence and colony counts. Variation in chain
length was scored by phase-contrast microscopy. S. gordonii
formed short chains of 2 to 30 individuals that did not vary be-
tween the different isolates (Table 1) and was not affected by
antibiotic treatment.
Titration of the system
Luciferase activity depends on several factors, including the
intracellular amount of the protein, its stability after antibiotic
addition, ATP concentration, and pH. Because these parame-
ters may change independently of cell viability,10,17 it was im-
portant to test the system in various physiological conditions
before running bactericidal experiments. First, we tested light
emission during normal growth and after inhibition of protein
synthesis with 20 times the MIC of chloramphenicol. Figure
2A indicates that luminescence was proportional to bacterial
growth. After addition of chloramphenicol, bacterial growth
came to a halt and viable counts marginally decreased over the
following 4 hr. This was accompanied by a parallel leveling of
light emission, which remained proportional to the viable
counts. Thus, “protein-inhibited” but viable cells expressed lu-
minescence for a prolonged period of time.
Second, we tested the physical and functional integrity of in-
tracellular luciferase after chloramphenicol addition. Cell ex-
tracts were prepared and analyzed both by Western blot and by
an “ex vivo” luminescence assay. In this condition, light emis-
sion depended on the exogenous adjustment of ATP and pH,
thus bypassing possible intracellular alterations. Figure 2B in-
dicates that luciferase remained physically and functionally un-
altered for several hours after inhibition of protein synthesis.
Thus, the stability and functionality of intracellular luciferase
remained stable for several hours in nonkilled cells.
Luciferase activity in bioluminescent S. gordonii
treated with ciprofloxacin and penicillin
The experiments were repeated with ciprofloxacin and peni-
cillin, two bactericidal drugs with different modes of action
(Fig. 3). After addition of 200 times the MIC of ciprofloxacin,
the cultures’ viable counts rapidly decreased by approximately
2 log CFU/ml over 4 hr (Fig. 3A). During the same time, the
cultures’ luminescence decreased in parallel by about 10 times,
demonstrating some correlation between viable counts and light
emission.
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FIG. 1. Correlation between luminescence and bacterial
growth in mutant LMI 2. Bacteria were grown in liquid cul-
tures and sampled at various times for both viable counts and
light emission. The data summarize a total of three indepen-
dent experiments. Luminescence is expressed in relative light
units (RLU) per second.
After addition of 200 times the MIC of penicillin, the viable
counts decreased at an average of 1 Log10 CFU/ml per 4–6 hr,
reaching 3–4 orders of magnitude after 24 hr (Fig. 3B and Table
1). This was slightly slower (by about 1 Log10 at 4 hr) than in
a previous report by Caldelari et al.2 The difference came from
the fact that Caldelari et al. added streptomycin to the growth
media to prevent bacterial contamination during serial passages.
Although their S. gordonii was streptomycin resistant, the ad-
dition of streptomycin slightly increased the rate of penicillin-
induced killing.
In the present experiments, in spite of relatively slow killing,
luminescence sharply dropped by $10 times within the first
hour of penicillin treatment, reaching background levels within
2 hr (Fig. 3B). This discordance between slow viable loss and
rapid switch off of luminescence was repeatedly observed in
six independent experiments with mutant LMI 2.
To determine further whether the phenomenon was related
to penicillin treatment rather than other coincidental phenom-
ena, the experiments were repeated with three tolerant deriva-
tives of S. gordonii carrying a luc reporter insert in indepen-
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FIG. 2. Correlation between luminescence and viable counts
in whole cultures (A) and cell extracts (B) before and after the
addition of 20 times the MIC of chloramphenicol. The arrows
indicate the time of drug addition. (A) Viable counts and lu-
minescence of either untreated (closed symbols) or chloram-
phenicol-treated cultures (open symbols). The upper part of B
depicts the luminescence of untreated (closed diamonds) or
treated cultures (open symbols), as well as the luminescence of
cell extracts as determined ex vivo (closed squares). The lower
part of B presents the amount of luciferase detected by West-
ern blot with either recombinant luciferase (rLuc), cell extracts
of the wild-type parent (WT), or cell extracts of mutant LIM 2
(Table 1) prepared 5 min before, or 2 and 4 hr after drug addi-
tion. It can be seen that luciferase was quantitatively and func-
tionally stable during chloramphenicol treatment. FIG. 3. Correlation between luminescence and bacterial
growth in mutant LMI 2 treated with 200 times the MIC of ei-
ther ciprofloxacin (A) or penicillin (B). Bacteria were grown in
liquid cultures and sampled at various times for luminescence
(dashed lines) and viable counts (continuous lines). Antibiotics
were added at time zero. Closed symbols represent untreated
control cultures and open symbols antibiotic-treated cultures. B
presents the mean 6 SD of three independent experiments.
dent genetic loci, namely Tol103, Tol104, and Tol105 (Table
1).2,3 Figure 4 indicates that, while these independent inser-
tional mutants were virtually immune of penicillin-induced
killing, they all demonstrated a disproportionate, sharp lumi-
nescence switch off during penicillin treatment. Thus, although
luminescence correlated with both chloramphenicol-induced in-
hibition and ciprofloxacin-induced killing of S. gordonii, it did
not correlate with penicillin-induced killing in this particular
organism.
Studies on the discordance between penicillin-induced
killing and luminescence
As already mentioned, bacterial chaining remained stable and
thus could not account for such discrepant results. Because
treatment with penicillin resulted in a rapid light switch off, we
tested whether inactivating the drug in situ could reverse the
phenomenon and switch the light on. Penicillin-treated cultures
were supplemented or not supplemented with penicillinase (fi-
nal concentration of 2000 U/ml; Bacto-Penase concentrate,
Difco) 2 hr after the addition of antibiotics. Figure 5 indicates
that while luminescence was rapidly switched off by penicillin,
it was readily restored after penicillin inactivation with peni-
cillinase. This $10 times luminescence “off/on” phenomenon
was very discordant with the relatively low variation in viable
counts during the same period of time. This suggested that peni-
cillin had altered either luciferase, or some intracellular factor
essential for luminescence, independently of bacterial viability.
This observation could be due either to luciferase degrada-
tion or to some metabolic alteration affecting the function of
the enzyme. Both possibilities were tested in cell lysates. As in
the chloramphenicol experiment, Western blots indicated that
luciferase remained present in the cells in spite of penicillin
treatment (Fig. 6). Thus, the decrease of luminescence was not
due to protein hydrolysis. On the other hand, luciferase could
not be reactivated in lysates of penicillin-treated bacteria, in
spite of ATP and pH adjustment. Thus, in contrast to the chlor-
amphenicol experiment, luciferase was functionally inactive af-
ter penicillin treatment.
Penicillin-induced alteration of luminescence depends
on de novo protein synthesis
The fact that the luminescence deficit persisted in cell ex-
tracts suggested the possible presence of an inhibitor. One can-
didate was penicillin itself. However, neither penicillin (2
mg/L), nor chloramphenicol (640 mg/L) affected the function
of recombinant luciferase when added to the system in vitro.
Another possibility was that bacteria treated with penicillin pro-
duced an inhibitor that was present in the cell lysates. A cross-
inhibition of luminescence was sought by mixing cell extracts
(final protein concentrations ranging from 2 to 80 mg/ml) from
S. gordonii cultures exposed for 2 and 4 hr to penicillin with
recombinant luciferase. No cross-inhibition was observed (data
not shown).
An additional possibility was that penicillin induced some
irreversible functional denaturation of luciferase. The question
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FIG. 5. Restoration of luminescence after inactivation of
penicillin with penicillinase. Broth cultures of mutant LMI 2
were treated (open symbols) or not treated (closed symbols)
with 200 times the MIC of penicillin, and both luminescence
(dashed lines) and viable counts (continuous lines) were fol-
lowed. Two hours after penicillin addition, the drug was inac-
tivated with an excess of penicillinase (arrows). The prompt
restoration of luminescence and the slow resumption of bacte-
rial growth is depicted by the dotted lines.
FIG. 4. Viable counts (closed symbols and plain lines) and
luminescence (open symbols and dotted lines) of three tolerant
mutants of S. gordonii carrying a luciferase reporter insert in
various genes treated with 200 times the MIC of penicillin. Mu-
tant Tol103 (squares) was described elsewhere,2 and carries a
luciferase-reporter insert in the arcB gene. Mutant Tol104 (tri-
angles) has the same tolerant background as Tol103,2 but car-
ries the luciferase reporter insert of LMI2, transferred by DNA
transformation. Mutant Tol105 (circles) has the same back-
ground as Tol103,2 but carries a luciferase insert in the scaA
gene.3 Bacteria were processed as in Fig. 3. Penicillin was
added at time zero.
then arose as to whether the “off/on” phenomenon depended on
de novo protein synthesis. This issue was addressed by adding
chloramphenicol 5 min after penicillinase to penicillin-treated
cultures. Figure 7 indicates that inhibiting de novo protein
synthesis with chloramphenicol after penicillin inactivation
blocked the restoration of luminescence. This supported the hy-
pothesis that light restoration depended on newly made pro-
teins.
DISCUSSION
The present experiments attempted to correlate the bacterio-
static and bactericidal effects of various drugs with luciferase
activity in bioluminescent S. gordonii. The results indicated that
the correlation depended on the drug class.
After addition of the protein inhibitor chloramphenicol, bac-
terial growth came to a halt. Light emission stopped increas-
ing, and luminescence remained proportional to the culture vi-
able counts. Moreover, luciferase could be recovered in a
functional state from cell extracts. Thus, luciferase that had ac-
cumulated in the cells before antibiotic treatment remained both
physically and functionally stable. Moreover, the surviving cells
kept enough metabolic energy to activate luciferase. This was
in agreement with previous studies reporting a “functional”
half-life of luciferase varying between 2 and 4 hr after treat-
ment of S. mutans and M. smegmatis with protein inhibitors in-
cluding tetracycline, chloramphenicol, and streptomycin.17,27,31
When high concentrations of ciprofloxacin were used, the
rapid decrease in bacterial viability was accompanied by a
roughly parallel drop in luminescence. Because quinolones do
not directly affect protein synthesis, the decrease in light emis-
sion was presumably due to killing-related de-energizing of the
cells. This suggests that the system might be considered to fol-
low the bactericidal effect of these kinds of molecules.
On the other hand, penicillin treatment resulted in a dis-
proportional drop of luminescence when compared to viable
counts. This contrasted with chloramphenicol and cipro-
floxacin, and prohibited any correlation between light emis-
sion and the bactericidal effect of this particular drug. This
discordance was observed both in the penicillin-killed LMI 2
and in a series of tolerant derivatives carrying luc reporter in-
serts in independent genetic loci. Thus, the phenomenon was
related to penicillin treatment rather than to coincidental ge-
netic constructs. Eventually, luminescence switch off did not
result from alteration in luciferase transcription, because the
protein was continuously present and physically stable after
penicillin addition.
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FIG. 6. The upper panel depicts the luminescence of whole
cultures and cell extracts during penicillin treatment of mutant
LMI 2. Bacterial cultures were treated (open symbols) or not
treated (closed symbols) with 200 times the MIC of penicillin
at time zero. Luminescence was determined in whole cultures
(diamonds) or cell extracts (squares) at various times thereafter.
The lower panel presents the amount of luciferase detected by
Western blot in either the wild-type parent (WT) or cell extracts
of mutant LIM 2 (Table 1) prepared 5 min before, or 1, 2, and
4 hr after drug addition. It can be seen that while luciferase was
quantitatively stable, it was functionally unstable during peni-
cillin treatment.
FIG. 7. The restoration of luminescence after penicillin inac-
tivation is inhibited by chloramphenicol. The experiment of Fig.
5 was repeated. However, after penicillinase addition, the cul-
tures were either left to recover as above (dotted lines) or sup-
plemented with 20 times the MIC of chloramphenicol (open 
triangles). It can be seen that chloramphenicol blocked lumi-
nescence restoration.
Several factors might be incriminated in this luminescence
defect. Previous studies showed that alterations in ATP or pH
were critical.6 In addition, products of the luciferase-luciferin
reaction including ADP and inorganic phosphorus decrease lu-
minescence as well.6 However, ATP and pH were not respon-
sible because adjustment of these parameters in cell extracts
could not restore luminescence. Alternatively, penicillin treat-
ment could have either induced the production of an inhibitor
or promoted some kind of post-translational modification. Be-
cause the restoration of luminescence after penicillin inactiva-
tion required de novo protein synthesis, the hypothesis of a post-
translational modification was the most likely one.
The penicillin-induced light switch off is reminiscent of the
fact that inhibiting penicillin-binding proteins with b-lactams
has a more complex physiological consequence than mere
blockage of peptidoglycan assembly. The most dramatic irre-
versible consequence is the triggering of autolysins, resulting
in wall degradation, cell lysis, and bacterial death.33 However,
this was not the case in the present study.
Reversible alterations include a number of metabolic changes
that are independent of cell death. For instance, penicillin-treat-
ment of S. aureus, S. mutans, and S. pneumoniae result in a
rapid switch off of RNA and protein synthesis.13,19,21 In S. pneu-
moniae, the decrease in macromolecule synthesis was identical
in both wild-type and tolerant pneumococci, in spite of .3 log
differences between viability losses after 4 hr of drug expo-
sure.19 Moreover, after inactivation of penicillin with penicil-
linase, protein synthesis was restored with a kinetic similar to
that of luminescence in the luciferase-producing S. gordonii.20
This suggests the existence of a “talk back” mechanism,13 ca-
pable of blocking the synthetic apparatus in response to abnor-
mal wall metabolism, irrespective of the bacterial survival.
Although this regulatory switch is not known, two b-lactam-
dependent regulatory pathways were described recently. In en-
terobacteria, a complex of four determinants (AmpC, AmpR,
AmpG, and AmpD) can sense the degradation of cell wall dur-
ing b-lactam treatment, and derepress the chromosomal
cephalosporinase AmpC.14 In S. aureus, the transmembrane
sensor-transducer (BlaRI) detects the presence of extracellular
penicillin35 and triggers the autocleavage of its cytoplasmic por-
tion—a metalloprotease. The free metalloprotease then cleaves
the penicillinase repressor (BlaI) and thus induced penicillinase
(BlaZ).
In the present study, intracellular luciferase did not undergo
proteolytic cleavage, as indicated by its unaltered electrophoretic
mobility. However, other types of post-translational modifi-
cations might exist. Firefly luciferase belongs to a superfam-
ily of adenylate-forming enzymes found in both eukaryotic
and prokaryotic cells. It includes aminoacyl-tRNA syn-
thetases, acyl-CoA ligases, gramicidine S and tyrocidine syn-
thetases, and the first enzyme of the penicillin biosynthetic
pathway.32 Aminoacyl-tRNA synthetase and acyl-CoA ligase
are involved in protein synthesis and energy metabolism. Such
enzymes might be under the control of some transcriptional
or translational regulation linked to macromolecule synthesis,
and hence affected by penicillin. Because of its homology at
the active site, the luciferase function might be down-regu-
lated simultaneously with these enzymes.4 The model is spec-
ulative and could include a number of metabolic and/or 
signaling intermediates. Some kind of post-translational mod-
ification would most likely fit with the observation described
herein. Thus, introducing reporter enzymes sharing mechanis-
tic homologies with normal metabolic reactions might reveal
other effects than those expected.
In conclusion, while luminescence could be used as a global
indicator for the bacteriostatic activity of antibiotics, it was
not reliable to dissociate between growth inhibition and bac-
terial killing by penicillin. Recently, such a system was used
to rapidly assess the bactericidal effect of a b-lactam in a
model of experimental thigh infection in mice.9 Decreased lu-
minescence measured in vivo correlated with bacterial eradi-
cation. The present experiments suggest that luminescence can
paradoxically decrease in inhibited, but nonkilled bacteria.
Additional experiments with tolerant mutants would be use-
ful to settle this issue. The killing-independent switch off of
luminescence during penicillin treatment is intriguing. The ob-
servation stirs new thinking into pending questions regarding
the “physiological” response of bacteria to cell wall inhibi-
tion.
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